Clinical trials: Bladder Wall Thickness
Urinary Incontinence
A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder
The main aim of the study is to investigate whether taking Tolterodine for overactive bladder symptoms can reduce the thickness of the bladder wall, as measured by intra-vaginal ultrasound.
- Trial name
- NCT00137397
- Testing
- Tolterodine ER
- Where
- 11 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Detrusor Overactivity, Overactive Bladder
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.
- Trial name
- SHRINK (NCT01093534)
- Testing
- solifenacin
- Where
- 79 sites in United States, Austria and 18 more
- Volunteers
- 547 people
- Sponsor
- Astellas Pharma Inc